ID   LXFL 529L
AC   CVCL_D085
SY   LXFL-529L; LXFL529L; LXF 529 L; LXFL-529; LXFL 529; LXFL529; LXF 529
DR   EFO; EFO_0006642
DR   ArrayExpress; E-MTAB-2706
DR   BioSample; SAMN03472856
DR   ChEMBL-Cells; CHEMBL3307537
DR   ChEMBL-Targets; CHEMBL614110
DR   Cosmic; 1802292
DR   Cosmic; 1870262
DR   EGA; EGAS00001000610
DR   GEO; GSM206521
DR   GEO; GSM274791
DR   GEO; GSM274825
DR   NCI-DTP; LXFL 529
DR   PharmacoDB; LXFL529_873_2019
DR   PubChem_Cell_line; CVCL_D085
DR   Wikidata; Q54903307
RX   PubMed=2041050;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=26589293;
WW   https://dtp.cancer.gov/discovery_development/nci-60/cell_list.htm
CC   HLA typing: A*01:01,01:01; B*14:02,37:01; C*06:02,06:02 (PubMed=26589293).
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Misspelling: LXPL 529; Note=Occasionally.
ST   Source(s): PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 10,11
ST   D13S317: 13
ST   D16S539: 10,11
ST   D18S51: 13
ST   D21S11: 28,29
ST   D3S1358: 15,17
ST   D5S818: 10,11
ST   D7S820: 8,12
ST   D8S1179: 11,15
ST   FGA: 20,21
ST   Penta D: 11,13
ST   Penta E: 12
ST   TH01: 9.3
ST   TPOX: 9
ST   vWA: 18
DI   NCIt; C2926; Lung non-small cell carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 05-10-23; Version: 21
//
RX   PubMed=2041050; DOI=10.1093/jnci/83.11.757;
RA   Monks A., Scudiero D.A., Skehan P., Shoemaker R.H., Paull K.D.,
RA   Vistica D.T., Hose C.D., Langley J., Cronise P., Vaigro-Wolff A.,
RA   Gray-Goodrich M., Campbell H., Mayo J.G., Boyd M.R.;
RT   "Feasibility of a high-flux anticancer drug screen using a diverse
RT   panel of cultured human tumor cell lines.";
RL   J. Natl. Cancer Inst. 83:757-766(1991).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//